Sign in to continue:

Saturday, August 1st, 2026

SafeSpace Global Corporation Appoints Michael L. Hrynuik Under New Employment Agreement – Form 8-K Filing June 2026

SafeSpace Global Corporation Files Form 8-K: Executive Appointment and Employment Agreement Details Announced

Key Points:

  • SafeSpace Global Corporation (“SSGC”) filed a Form 8-K with the SEC dated June 15, 2026, reporting a significant executive appointment and new employment terms.
  • Michael L. Hrynuik was appointed, with a comprehensive employment agreement outlining compensation, bonuses, equity grants, and performance targets.
  • The company’s common stock trades on the OTC Bulletin Board under the symbol “SSGC.”

Details of the Executive Appointment:

  • On June 15, 2026, SSGC announced the appointment of Michael L. Hrynuik via a new employment agreement.
  • Compensation includes a base salary, annual performance bonus, and substantial equity incentives, indicating a strong commitment to executive retention and performance.

Bonus Structure and Performance Targets:

  • The executive is eligible for an annual bonus of up to 30% of annual salary, contingent upon achieving key performance goals determined by the CEO and Board of Directors.
  • Key goals for bonus eligibility include:
    • Assisting in raising bridge financing and engaging with investors and legal counsel to complete financing efforts.
    • Attending Board of Directors and weekly executive meetings.
    • Chairing monthly financial review meetings with senior management and communicating regularly with the Audit Committee Chair.
    • Improving accounting processes, moving toward monthly closings, monitoring accounting tasks, and working with auditors for a 2025 re-audit.
    • Assisting with SEC filings (including 10-Q, 10-K, 8-K, and Forms 3 and 4).
    • Enhancing annual budgeting, developing rolling forecasts, and working toward uplisting the company to a recognized stock exchange (American, Nasdaq, NYSE).
    • Monitoring cash burn, creating and enforcing spending policies, and developing a 13-week cash flow model for management.
    • Establishing a Human Resources Committee to evaluate employee policies and salary ranges, including for international staff.
    • Reviewing and enhancing internal controls, developing and reporting Key Performance Indicators, reviewing press releases, and assisting in SOC II compliance efforts.
  • Bonus achievement is measured objectively and paid unless the Compensation Committee reasonably determines otherwise.

Equity Incentives:

  • The Executive is granted a non-qualified stock grant of 2,000,000 shares of SSGC common stock, with vesting as follows:
    • 666,667 shares vest initially, with the remainder subject to performance and tenure milestones.
  • This substantial equity grant aligns the executive’s interests with shareholders and may impact share dilution and price sensitivity.

Price Sensitive and Investor-Relevant Information:

  • The appointment and terms of the employment agreement, especially the large equity grant, could have material implications for share value, investor confidence, and company strategy.
  • The focus on bridge financing and uplisting to a major exchange are potentially transformative events that shareholders should monitor closely.
  • Performance targets indicate a strong focus on financial discipline, compliance, and operational improvements.
  • SEC filings, audits, and internal controls enhancements may improve transparency and investor trust.

Other Notable Information:

  • SSGC is not classified as an emerging growth company.
  • There were no written communications, soliciting material, or tender offer communications associated with this filing.

What Shareholders Should Watch:

  • Progress on bridge financing and uplisting efforts, as these could significantly alter the company’s market profile and liquidity.
  • Impact of the stock grant on share dilution and executive alignment.
  • Operational and financial improvements as outlined in the executive’s performance targets.

Disclaimer:
This article is based on publicly disclosed SEC filings and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence or consult professional advisors before making investment decisions. The information herein may be subject to change and should not be relied upon as definitive or exhaustive.

View SafeSpace Global Corp Historical chart here



Aspire Biopharma Holdings (ASBPW) 8-K Filing: Shareholder Vote Results and Company Details June 2026

Aspire Biopharma Holdings, Inc. – Special Meeting Results an...